Uncategorized

Novo Nordisk Falls Most on Record After New Weight Drug Disappoints – Bloomberg

Posted on Author Comments Off on Novo Nordisk Falls Most on Record After New Weight Drug Disappoints – Bloomberg
  1. Novo Nordisk Falls Most on Record After New Weight Drug Disappoints  Bloomberg
  2. Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it  CNN
  3. Novo Nordisk shares plunge 17% after disappointing trial results; Lilly jumps in premarket  CNBC
  4. Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar.  Barron’s
  5. Novo Nordisk A/S (NVO) Fell as its Weight Loss Drug Faced Supply Constraints  Yahoo Finance